רווח תפעולי לפני פחת: cogrx.com (CGTX)

The reliability of Cognition Therapeutics (CGTX) is based on robotic IT analysis of synaptic proteins. The size of cash EBITDA confirms the effectiveness of this strategy, while 0.00 reflects the latest level of the metric. Additional stability is provided by partnerships with gerontology centers fighting Alzheimer's and the proficient management of contract research organizations to conduct clinical trials.
פילוחי נתונים אנליטיים מרוכזים עבור Cognition Therapeutics (CGTX)

This indicator determines the business's actual ability to generate cash flow from core operations, excluding non-cash charges and tax adjustments. Analyzing EBITDA allows for an assessment of the effectiveness of Cognition Therapeutics (CGTX) investments in the development of Alzheimer's disease drugs and the cost of its research and development collaborations with specialized aging institutes.